Literature DB >> 23215850

Lipopolysaccharide preconditioning attenuates neuroapoptosis and improves functional recovery through activation of Nrf2 in traumatic spinal cord injury rats.

Wei-Chao Li1, Dian-Ming Jiang, Ning Hu, Xiao-Tong Qi, Bo Qiao, Xiao-Ji Luo.   

Abstract

The previous studies suggested that low-dose lipopolysaccharide (LPS) provides neuroprotection against subsequent challenge with ischemic/reperfusion injury in the brain. But there were few reports about the neuroprotective effects of low-dose LPS against spinal cord injury (SCI). In this study, we evaluated the effect of low-dose LPS preconditioning on neuroapoptosis status after traumatic SCI (TSCI), using a standardized contusion model (NYU, New York University, impactor). SCI-induced rats were randomly divided into three groups: sham operation, control (receiving only normal saline) and LPS preconditioning (0.2 mg/kg, ip; 72 hours before injury). Neurologic function was assessed by the Basso, Beattie and Bresnahan (BBB) score at 6, 12, 24, 48 and 72 hours after TSCI. Rats were sacrificed at 72 hours postinjury. Histological changes were studied using Nissl staining. Apoptotic neural cells were assessed using the TdT-mediated dUTP Nick End Labeling (TUNEL) assay. Nuclear factor erythroid 2-related factor 2 (Nrf2) and caspase-3 were detected with immunohistochemistry and Western blot. LPS preconditioning reduced neuron apoptosis, improved neurologic outcome and actived Nrf2 expression. Moreover, Histological changes and the number of apoptotic cells were correlated with Nrf2 expression after the rats suffered the SCI. Our results suggest that LPS preconditioning exerted a neuroprotective effect against TSCI in rats, and activation of Nrf2 was believed to be one of the contributing mechanisms.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23215850     DOI: 10.3109/00207454.2012.755181

Source DB:  PubMed          Journal:  Int J Neurosci        ISSN: 0020-7454            Impact factor:   2.292


  7 in total

1.  Preconditioning by Low Dose LPS Prevents Subsequent LPS-Induced Severe Liver Injury via Nrf2 Activation in Mice.

Authors:  Masato Nakasone; Kazuhiro Nakaso; Yosuke Horikoshi; Takehiko Hanaki; Yoshinori Kitagawa; Toru Takahashi; Yoshimi Inagaki; Tatsuya Matsura
Journal:  Yonago Acta Med       Date:  2016-09-12       Impact factor: 1.641

Review 2.  Recent Advances in the Role of Nuclear Factor Erythroid-2-Related Factor 2 in Spinal Cord Injury: Regulatory Mechanisms and Therapeutic Options.

Authors:  Tianqi Jiang; Yongxiong He
Journal:  Front Aging Neurosci       Date:  2022-06-10       Impact factor: 5.702

3.  Lipopolysaccharide pretreatment inhibits LPS-induced human umbilical cord mesenchymal stem cell apoptosis via upregulating the expression of cellular FLICE-inhibitory protein.

Authors:  Yu Sen Hou; Ling Ying Liu; Jia Ke Chai; Yong Hui Yu; Hong Jie Duan; Quan Hu; Hui Nan Yin; Yi He Wang; Shu Bo Zhuang; Jun Fan; Wan Li Chu; Li Ma
Journal:  Mol Med Rep       Date:  2015-05-04       Impact factor: 2.952

4.  Effects of ginsenoside Rb1 on oxidative stress injury in rat spinal cords by regulating the eNOS/Nrf2/HO-1 signaling pathway.

Authors:  Xinwei Liu; Xiaochuan Gu; Miaomiao Yu; Ying Zi; Hailong Yu; Yu Wang; Yanchun Xie; Liangbi Xiang
Journal:  Exp Ther Med       Date:  2018-06-12       Impact factor: 2.447

5.  Therapeutic and Prophylactic Effects of Amphotericin B Liposomes on Chronic Social Defeat Stress-Induced Behavioral Abnormalities in Mice.

Authors:  Jiashu Lu; Chao Huang; Qun Lu; Xu Lu
Journal:  Front Pharmacol       Date:  2022-07-15       Impact factor: 5.988

6.  Transplantation of erythropoietin gene-modified neural stem cells improves the repair of injured spinal cord.

Authors:  Min-Fei Wu; Shu-Quan Zhang; Rui Gu; Jia-Bei Liu; Ye Li; Qing-San Zhu
Journal:  Neural Regen Res       Date:  2015-09       Impact factor: 5.135

Review 7.  The emerging role of long non-coding RNA in spinal cord injury.

Authors:  Zhongju Shi; Bin Pan; Shiqing Feng
Journal:  J Cell Mol Med       Date:  2018-02-01       Impact factor: 5.310

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.